NCT05048212 2026-04-09A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesM.D. Anderson Cancer CenterPhase 2 Recruiting20 enrolled
NCT06047379 2026-03-02Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisNeonc Technologies, Inc.Phase 1/2 Recruiting134 enrolled
NCT04511013 2025-09-11A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesSWOG Cancer Research NetworkPhase 2 Recruiting112 enrolled
NCT06712927 2025-09-08Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesStanford UniversityPhase 2 Recruiting60 enrolled